:paricalcitol(ref.brand: Zemplar®(us &eu) Generics - Manufacturers & Suppliers
| Product/Composition:- | :Paricalcitol(Ref.Brand: Zemplar®(US &EU) Generics |
|---|---|
| Strength:- | Capsules: 1 mcg 2 mcg 4 mcg & Injection: 2 mcg/mL , 5 mcg/mL |
| Form:- | Capsules and Injection |
| MOQ | MOQ |
| Get Quote Send Enquiry on WhatsApp | |
Paricalcitol (Zemplar®) is a selective vitamin D receptor activator used to manage secondary hyperparathyroidism in CKD patients, available as oral capsules and IV injection. Approved in both the EU and US, it offers targeted PTH control with a lower risk of hypercalcemia and hyperphosphatemia. Suitable for hospital tenders, licensing, and distribution in the global renal care market.
Paricalcitol, marketed as Zemplar®, is a selective vitamin D receptor activator used to treat secondary hyperparathyroidism in patients with chronic kidney disease (CKD), both on dialysis (stage 5) and in pre-dialysis stages (3–4). It effectively lowers parathyroid hormone (PTH) levels while minimizing the risk of hypercalcemia and hyperphosphatemia. Available as oral capsules (1 mcg, 2 mcg, 4 mcg) and IV injection (2 mcg/mL, 5 mcg/mL), Paricalcitol is approved in both the US (FDA) and EU (EMA). It is a key therapeutic in nephrology and an excellent B2B opportunity for licensing, distribution, and hospital-based partnerships in regulated markets.
